ALUMIS INC.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
ALMS$6.40-2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| | Six Months Ended June 30, | |||||
| (in thousands) · · 2025 · 2024 | ||||||
| Cash flows from operating activities · · | ||||||
| Net loss | | $(39,642) | | $(106,357) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Stock-based compensation | | 25,630 | | 5,790 | ||
| Net accretion of discounts on marketable securities | | (2,152) | | (507) | ||
| Depreciation and amortization | | 1,713 | | 1,518 | ||
| Non-cash lease expense | | 624 | | 12 | ||
| Loss on disposal of fixed assets | | — | | 5 | ||
| Change in fair value of derivative liability | | — | | 5,406 | ||
| Gain on bargain purchase in connection with the ACELYRIN Merger | | | (187,907) | | | — |
| Changes in operating assets and liabilities: | | | | | ||
| Research and development prepaid expenses | | 7,373 | | (10,540) | ||
| Other prepaid expenses and other assets | | 96 | | (382) | ||
| Other assets, non-current | | | (1,723) | | | — |
| Accounts payable | | (1,162) | | 7,788 | ||
| Deferred revenue | | | 2,611 | | | — |
| Research and development accrued expenses | | 11,037 | | 3,638 | ||
| Other accrued expenses and current liabilities | | 6,537 | | (1,912) | ||
| Operating lease liabilities | | | (1,349) | | | (1,007) |
| Other liabilities, non-current | | | 168 | | | — |
| Deferred income tax liability | | (8,561) | | — | ||
| Net cash used in operating activities | | (186,707) | | (96,548) | ||
| Cash flows from investing activities | | | ||||
| Maturities of marketable securities | | 144,274 | | 8,000 | ||
| Purchases of marketable securities | | (24,535) | | (58,964) | ||
| Purchases of property and equipment | | | (653) | | | (587) |
| Cash, cash equivalents and restricted cash acquired in connection with the ACELYRIN Merger | | 49,742 | | — | ||
| Net cash provided by (used in) investing activities | | 168,828 | | (51,551) | ||
| Cash flows from financing activities | | | ||||
| Proceeds from issuance of redeemable convertible preferred stock and derivative liability, net of issuance costs | | — | | 258,461 | ||
| Proceeds from issuance of common stock upon exercise of stock options | | — | | 537 | ||
| Repurchase of common stock shares issued upon early exercised restricted common stock | | | (17) | | | — |
| Proceeds from issuance of common stock under the 2024 ESPP | | | 766 | | | — |
| Payments of deferred offering costs | | — | | (1,787) | ||
| Net cash provided by financing activities | | 749 | | 257,211 | ||
| Net (decrease) increase in cash, cash equivalents and restricted cash | | (17,130) | | 109,112 | ||
| Cash, cash equivalents and restricted cash at beginning of period | | 170,632 | | 47,133 | ||
| Cash, cash equivalents and restricted cash at end of period | | $153,502 | | $156,245 | ||
| Supplemental disclosures: | | | ||||
| Equity consideration transferred in connection with the ACELYRIN Merger | | $238,077 | | $— | ||
| Vesting of early exercised stock options and unvested restricted shares of common stock | | $410 | | $759 | ||
| Purchases of property and equipment in other accrued expenses and current liabilities | | $— | | $716 | ||
| Right-of-use assets obtained in exchange for operating lease liabilities | | $1,776 | | $— | ||
| Recognition of derivative liability upon issuance of redeemable convertible preferred stock | | $— | | $8,913 | ||
| Settlement of derivative liability upon issuance of redeemable convertible preferred stock | | $— | | $(14,319) | ||
| Deferred offering costs in accounts payable and other accrued expenses and current liabilities | | $— | | $2,559 | ||
| Reconciliation of cash, cash equivalents and restricted cash: | | | | |||
| Cash and cash equivalents | | $151,753 | | $155,108 | ||
| Restricted cash | | 367 | | 113 | ||
| Restricted cash, non-current | | 1,382 | | 1,024 | ||
| Total cash, cash equivalents and restricted cash | | $153,502 | | $156,245 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.